(E)-3-(4-methoxy-2-phenylphenyl)prop-2-enoic acid | 1417997-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(4-methoxy-2-phenylphenyl)prop-2-enoic acid
• CAS: 1417997-83-1
• 化学式: C₁₆H₁₄O₃
• 分子量: 254.285
• InChiKey: NUEDEXYPLSFNRQ-CSKARUKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-methoxy-2-phenylphenyl)prop-2-enoic acid 、 氯甲酸乙酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Synthesis and Biological Evaluation ofortho-ArylN-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors

  摘要：

  AbstractHistone deacetylases (HDACs) are a family of enzymes that play a crucial role in biological process and diseases. In contrast to other isozymes, HDAC8 is uniquely incapable of histone acetylation. In order to delineate its physiological function, we developed HDAC8‐selective inhibitors using knowledge‐based design combined with structural modeling techniques. Enzyme inhibitory analysis demonstrated that some of the resulting compounds (22 b, 22 d, 22 f, and 22 g) exhibited anti‐HDAC8 activity superior to PCI34051, a known HDAC8‐specific inhibitor, with IC50 values in the range of 5–50 nM. Among them, compound 22 d showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1‐5); it exhibited cytotoxicity against human lung CL1‐5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR‐90 cells. Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1‐5 is higher than that in H1299 and CL1‐1 cells, a result consistent with the differential cytotoxicity of compound 22 d. These results suggest the effectiveness of our design concept, which may lead to a tool compound for studying the specific role of HDAC8 in cellular biological processes.

  DOI：

  10.1002/cmdc.201200300
• 作为产物：
  描述：

  7-甲氧基香豆素 在 吡啶 、 四(三苯基膦)钯 、 potassium carbonate 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 (E)-3-(4-methoxy-2-phenylphenyl)prop-2-enoic acid
  参考文献：
  名称：

  Synthesis and Biological Evaluation ofortho-ArylN-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors

  摘要：

  AbstractHistone deacetylases (HDACs) are a family of enzymes that play a crucial role in biological process and diseases. In contrast to other isozymes, HDAC8 is uniquely incapable of histone acetylation. In order to delineate its physiological function, we developed HDAC8‐selective inhibitors using knowledge‐based design combined with structural modeling techniques. Enzyme inhibitory analysis demonstrated that some of the resulting compounds (22 b, 22 d, 22 f, and 22 g) exhibited anti‐HDAC8 activity superior to PCI34051, a known HDAC8‐specific inhibitor, with IC50 values in the range of 5–50 nM. Among them, compound 22 d showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1‐5); it exhibited cytotoxicity against human lung CL1‐5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR‐90 cells. Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1‐5 is higher than that in H1299 and CL1‐1 cells, a result consistent with the differential cytotoxicity of compound 22 d. These results suggest the effectiveness of our design concept, which may lead to a tool compound for studying the specific role of HDAC8 in cellular biological processes.

  DOI：

  10.1002/cmdc.201200300

文献信息

• End modified thermal responsive hydrogels
  申请人：——

  公开号：US20030092776A1

  公开（公告）日：2003-05-15

  A pharmaceutic composition includes a pharmaceutically acceptable carrier, comprising a reverse thermally viscosifying polymer. The polymer includes a linear block copolymer, wherein at least one block comprises a poloxamer; and at least one block comprises a biocompatible polymer or oligomer, in an aqueous medium. The composition also includes an active agent which imparts a pharmaceutic or cosmetic effect. The composition viscosifies in response to an environmental stimulus. The composition is suitable for administration of the pharmaceutical agent across dermal, otic, rectal, vaginal, ophthalmic, esophageal and nasal mucosal membranes.

  一种药物组合物包括一种药学上可接受的载体，其中包含一种反向热粘性聚合物。聚合物包括线性嵌段共聚物，其中至少一个嵌段包括聚氧乙烯；至少一个嵌段包括水介质中的生物相容性聚合物或低聚物。该组合物还包括一种活性剂，可产生药用或美容效果。该组合物在环境刺激下会发生粘化。该组合物适合在皮肤、耳、直肠、阴道、眼、食道和鼻粘膜上施用药剂。
• COMPOSITIONS FOR COSMETIC APPLICATIONS
  申请人：MedLogic Global Corporation

  公开号：EP1011609A1

  公开（公告）日：2000-06-28
• EP1011609A4
  申请人：——

  公开号：EP1011609A4

  公开（公告）日：2000-08-16
• US6316011B1
  申请人：——

  公开号：US6316011B1

  公开（公告）日：2001-11-13
• US7008628B2
  申请人：——

  公开号：US7008628B2

  公开（公告）日：2006-03-07